Salix Pharmaceuticals (SLXP) Said Trials Show Statistically Significance
More News related to SLXP
- Summer Street Initiates Coverage of Salix Pharmaceuticals (SLXP) with a Buy
- Notable Analyst Rating Changes 02/01: BIDU, ALV, G, ARG, ASH Upgraded; CPF, M, LZ, COGT, WCRX Downgraded
- Jefferies & Co Initiates Coverage on Salix Pharmaceuticals (SLXP) with a Buy
- Oppenheimer Upgrades Salix Pharmaceuticals (SLXP) to Outperform
- Salix (SLXP) February volatility at 58, April at 73 into FDA meeting
More News related to FDA
- Celsion Corp. (CLSN) Recommended to Continue Enrollments for ThermoDox Phase III
- Isis Pharmaceuticals (ISIS) Falls On Safety Concerns
- AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
- Curis (CRIS) Announces Publication of CUDC-101 Data
- Clarient (CLRT) Launches Lung Cancer Test Insight Dx Pulmotype
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).
In each trial rifaximin versus placebo treated patients demonstrated a statistically significant improvement for the primary endpoint of the adequate relief of IBS symptoms as assessed over one month (weeks 3, 4, 5 and 6) following completion of a 14-day course of therapy (weeks 1 and 2). Consistent with the primary endpoint in each trial, the key secondary endpoint of relief of IBS-related bloating also demonstrated statistical significance of rifaximin versus placebo in each trial. These two large confirmatory trials with 600 patients each were conducted following the previously reported positive results from a Phase 2 trial.
Related Categories
FDAStocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
